UVA-1 Therapy for Sclerosing Skin Diseases
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate how well UVA-1 therapy (a type of light therapy) alleviates symptoms in people with specific skin conditions. It focuses on individuals with systemic scleroderma, morphea, or sclerodermatous Graft-Versus-Host Disease, which cause skin hardening. Participants will undergo 30 UVA-1 treatment sessions and report on their skin's condition before and after. The trial seeks individuals diagnosed with one of these skin conditions who can commit to 30 treatment sessions over approximately three months. As an unphased trial, this study offers participants the chance to contribute to understanding how UVA-1 therapy can improve skin conditions.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What prior data suggests that UVA-1 therapy is safe for treating sclerosing skin diseases?
Research has shown that UVA-1 therapy is generally safe for treating skin conditions like systemic scleroderma and morphea. In one study, all patients who received high doses of UVA-1 therapy noticed softer skin, and some even experienced complete resolution of their skin issues. Another study found that UVA-1 therapy was well-tolerated, with 83.3% to 100% of patients improving, depending on the dose.
While most patients experience positive results, these studies did not detail specific side effects. However, the regular use and reported improvements suggest that serious side effects are rare. If considered for other conditions, this information provides reassurance about UVA-1 therapy's safety.12345Why are researchers excited about this trial?
Researchers are excited about UVA-1 Therapy for sclerosing skin diseases because it offers a unique approach compared to traditional treatments like corticosteroids and immunosuppressive drugs. Unlike these standard treatments, which work by broadly dampening the immune system, UVA-1 Therapy uses a specific range of ultraviolet light to target the skin directly and potentially reduce fibrosis. This method not only provides a non-invasive alternative but may also minimize systemic side effects, making it a promising option for patients seeking relief with fewer risks.
What evidence suggests that UVA-1 therapy might be an effective treatment for sclerosing skin diseases?
Research has shown that UVA-1 therapy effectively treats several skin conditions, including scleroderma. In one study, all patients using high-dose UVA-1 therapy reported softer skin, with some experiencing complete clearing of their skin issues. Another study found improved skin flexibility and movement in patients. This therapy penetrates deeply into the skin, reducing the thickness and hardness of affected areas. Overall, UVA-1 therapy appears promising for improving symptoms in skin diseases that cause hardening.12678
Who Is on the Research Team?
Christopher B. Hansen, M.D.
Principal Investigator
University of Utah MidValley Dermatology
Are You a Good Fit for This Trial?
This trial is for adults over 18 with sclerosing skin diseases like systemic scleroderma, morphea, or Graft-Versus-Host Disease affecting the skin. Participants must be able to complete 30 UVA-1 therapy sessions within 100 days and provide consent. Pregnant individuals, those intolerant to UV light, or who have used UV therapy/tanning beds in the last month cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo 30 sessions of UVA-1 phototherapy to treat sclerosing skin diseases
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- UVA-1 Therapy
Trial Overview
The study aims to measure patient-reported improvements after undergoing 30 sessions of UVA-1 phototherapy for treating sclerosing skin conditions. It's a prospective trial where patients self-report outcomes and undergo clinical assessments before and after treatment.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Utah
Lead Sponsor
Citations
Efficacy of ultraviolet A1 phototherapy for inflammatory, ...
Conclusions: UVA1 phototherapy is an effective treatment for a variety of skin conditions. In most patients, at least eight treatments of a medium-high dosage ...
Patient Reported Outcomes with UVA-1 Therapy for ...
The purpose of this study is to assess the degree of improvement seen patient reported outcomes after 30 sessions of UVA-1 therapy in treating systemic ...
UVA1 a promising approach for scleroderma - PMC
All patients undergoing high-dose UVA1 therapy reported softening of sclerotic plaques, and complete clearance was observed in 4 of 10 patients. Whereas, 5 of 7 ...
Efficacy and Satisfaction of Low Doses UVA1 Phototherapy
UVA1 therapy has also been demonstrated to improve the symptomatology of cutaneous mastocytosis [39]. Stege et al. [40] reported improvement of symptoms in 4/4 ...
5.
cureus.com
cureus.com/articles/354292-effect-of-uv-a1-phototherapy-treatment-on-scleroderma-a-systematic-review.pdfEffect of UV-A1 Phototherapy Treatment on Scleroderma
Overall, patients who received UV-A1 phototherapy saw beneficial effects, including improvements in skin elasticity, mobility of extremities,.
UVA1 Phototherapy Is Safe and Effective for Sclerosing ...
Respectively, 20%, 83.3%, and 100% of systemic scleroderma patients treated with low-, medium- and high-dose UVA1 responded. A similar result ...
Low-dose UVA1 phototherapy for treatment of localized ...
According to clinical and ultrasound criteria, more than 80% of the sclerotic lesions disappeared or markedly improved during UVA1irradiation in 18 of the 20 ...
Morphea: The 2023 update - PMC - PubMed Central
Morphea, also known as localized scleroderma, is a rare inflammatory connective tissue disorder occurring primarily in children aged 2–14 years ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.